IntroductionPossibly fibromyalgia and migraine share similar pathophysiological mechanisms, generatingan imbalance of neurotransmitters involved in pain modulation, with increased neuronal excitability. The association between these two conditions is frequent, increasing the disability of both.ObjectivesWe aimed to review articles published in the last 20 years about the presence of fibromyalgiain patients with migraine and to analyze the quality of life of these patients.MethodsBased on a literature search in the major medical databases and using the descriptors “migraine” and “fibromyalgia” we include articles published between 2001 and 2021. We found 387 articles, but only five met the inclusion criteria.ResultsIn five articles analyzed, 429 patients with migraine were found, in which fibromyalgiawas present in 31.5% of them, predominantly in women (p<0.0001). In this association, there was a higher risk for depression and worse quality of life.ConclusionsThe association of fibromyalgia in patients with migraine is frequent, increasing the disabilityof these two diseases and generating great social impact. Knowledge of this association and the management of its consequences are necessary in medical practice.
IntroductionPropranolol was the first non-selective beta-adrenergic blocker to be developed. Initially it was used in the treatment of cardiovascular diseases, but since the 60's it has been used in the prevention of migraine.ObjectiveThe objective of this study was to know the history of propranolol and its use as a migraine prophylactic.MethodsThis study was an integrative literature review using articles with historical data on propranolol, from its origin in cardiology to its indication in the preventive treatment of migraine.ResultsPropranolol was described in 1962 for the treatment of cardiovascular diseases. In the same decade, it was prescribed for the preventive treatment of migraine and, recently, included in the consensus of the Brazilian Headache Society.ConclusionAlthough propranolol was initially synthesized for the treatment of heart disease, it has proved to be an effective drug in preventing migraine attacks.
Introduction: Hypnic headache is a rare primary headache disorder that occurs during sleep. Its pathophysiology is uncertain, but hypothalamic dysfunction is hypothesized. It is usually a primary headache, but it can have secondary causes. Objectives: We aimed was to review articles published in the last 34 years on hypnic headache and analyze secondary cases. Methods: Based on a literature search in the major medical databases and using the descriptor “hypnic headache” we included articles published between 1988 and 2020. Of the 359 patients found, only 18 met the inclusion criteria and were analyzed. Results: We found 18 patients (6 men and 12 women) with secondary hypnic headache. The mean age of patients was 58.7±15.0 years, ranging from 20 to 84 years. The causes of hypnic headache were attributed to cranial vascular disorder (five), to non-vascular intracranial disorder (six), to a substance or its withdrawal (three) and to disorder of homoeostasis (four). Conclusions: Although most cases of hypnic headache are primary, some symptomatic cases are described in the literature.
Introduction According to the International Classification of Headache Disorders (ICHD-3), dialysis headache has no specific characteristics occurring during and caused by haemodialysis. It resolves spontaneously within 72 hours after the haemodialysis session has ended. Objective To describe the prevalence, clinical features, associated symptoms and risk factors of dialysis headache. Methods Based on a literature search in the major medical databases and using the descriptors“dialysis headache”, “hemodialysis and headache” and “renal dialysis and headache”we included articles published between 1992 and 2022. Of the 492articles found, only 9 met the inclusion criteria and were analyzed. Results We describe 444 patients (53.1% men and 46.9% women) diagnosed with dialysis headache, corresponding to 24.8% of those who underwent hemodialysis.The age ranged from 15 to 75 years. Pain occurred predominantly from the third hour of hemodialysis (65.8%), lasting less than four hours (71.7%), located bilaterally (63.1%), pulsatile (58.5%) and moderate intensity (68.9%).The most frequent associated symptoms were photophobia or phonophobia (71.5%), vertigo (22.3%) and nausea and/or vomiting (16.5%). Conclusion This review showed a high prevalence of dialysis headache in patients undergoing hemodialysis and that the clinical characteristics, treatment and prevention are still poorly studied.
Objetivos: Apresentar um caso incomum de recidiva de fibroma ossificante complicado com osteomielite e piocele de seio frontal. Relato de caso: Paciente, 50 anos, com diagnóstico prévio de fibroma ossificante, tendo sido submetido a procedimento cirúrgico para excisão do tumor em face há 23 anos. Evoluiu há cerca de 1 ano com o aparecimento de orifícios fistulosos em face, com drenagem de secreção purulenta. Realizou tomografia computadorizada de seios paranasais que evidenciou a presença de trajetos fistulosos cutâneos em região frontal esquerda e frontotemporal direita, onde se evidencia pequena coleção abscessulizada adjacente ao plano meníngeo. O tratamento incluiu um acesso externo em face para a drenagem de coleção purulenta, além de antibioticoterapia prolongada. Conclusão: O fibroma ossificante de seios paranasais é de ocorrência rara. Seu tratamento cirúrgico é, muito frequentemente, desafiador para o cirurgião devido à proximidade com estruturas nobres, como encéfalo e órbita. Faz-se necessário o envolvimento de uma equipe multidisciplinar para um seguimento adequado dos pacientes e manejo das possíveis complicações pós-cirúrgicas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.